Compared effectiveness of TNF inhibitors, JAK inhibitors, and csDMARDs in naïve rheumatoid arthritis patients: a real-world, observational, multi-center, retrospective cohort study in Northwest China
Clinical Rheumatology · 2026
DOI: 10.1007/s10067-026-08082-2 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Rheumatology, 2026. Verfasst von Jiawei Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, PLA Specialized Research Institute of Rheumatology & Immunology, Xijing Hospital, Fourth Military Medical Universi…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Janus Kinase Inhibitors, Tumor Necrosis Factor Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: the Key-Area Research and Development Program of Shaanxi Province, the Chinese National Key Technology R&D Program, Ministry of Science and Technology.
Abstract (Originalsprache)
OBJECTIVE: The objective of this study is to compare the effectiveness of TNF inhibitors (TNFi), JAK inhibitors (JAKi), and conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) in the treatment of anti-citrullinated peptide antibody-positive (ACPA +) and anti-citrullinated peptide antibody-negative (ACPA -) naïve rheumatoid arthritis (RA) patients. METHODS: In this real-world, observational, multi-center, retrospective cohort study in northwest China, we investigated patients with a diagnosis of RA from October 2023 to August 2025. A total of 563 RA patients who met the 2010 ACR/EULAR classification criteria were included and treated with a TNFi (n = 63), a JAKi group (n = 119), and csDMARDs only (n = 381). All evaluation indicators across treatment groups (TNFi, JAKi, and csDMARDs-only) were analyzed by two-way ANOVA with Sidak's multiple comparison tests. RESULTS: RA patients receiving TNFi, JAKi, or csDMARDs-only experienced comparable clinical benefits. Both ACPA + and ACPA - patients exhibited similar responses among the three treatment groups, with no significant differences in the improvement of evaluation indicators such as HAQ-DI, VAS, PVAS, DVAS, DAS28_ESR, DAS28_CRP, SDAI, and CDAI. The csDMARDs-only group has the highest drug persistence rate at the 12th month among all groups. There are adverse events in the TNFi and JAKi groups, including one case of urinary tract infection, two cases of gastrointestinal reactions, and two cases of abnormal liver function. CONCLUSION: TNFi, JAKi, and csDMARDs-only exhibit similar efficacy in treating naïve RA patients, irrespective of ACPA status. In naïve RA patients, the initial combination of TNFi or JAKi does not have better clinical benefit. TRIAL REGISTRATION: This trial was retrospectively registered with the Chinese Clinical Trial Registry (ChiCTR, https://www.chictr.org.cn/index.html ), a Primary Registry in the World Health Organization International Clinical Trial Registry Platform (WHO ICTRP), under the identifier ChiCTR2300068472. Key Points • TNFi, JAKi, and csDMARDs-only showed similar effectiveness during 12 months in naïve patients. • ACPA status had no significant effect on the efficacy of TNFi, JAKi, and csDMARDs. • The drug persistence of csDMARDs-only is better than that of JAKi and TNFi within 12 months.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology, PLA Specialized Research Institute of Rheumatology & Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China.
- Department of Rheumatology, Yanan University Affiliated First Hospital, Yulin, Shaanxi, People's Republic of China.
- Department of Rheumatology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, People's Republic of China.
- Department of Rheumatology, Shaanxi Provincial Hospital of Integrated Traditional Chinese and Western Medicine, Xi'an, Shaanxi, People's Republic of China.
- Department of Clinical Immunology, PLA Specialized Research Institute of Rheumatology & Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China. zhengzh@fmmu.edu.cn.
- Department of Clinical Immunology, PLA Specialized Research Institute of Rheumatology & Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China. zhengyan@fmmu.edu.cn.
Förderung
- the Key-Area Research and Development Program of Shaanxi Province
- the Chinese National Key Technology R&D Program, Ministry of Science and Technology
Zitieren
APA
Wang, J., Xiao, G., Huo, A., Jiang, H., Li, R., Li, J., Li, X., Liu, Y., Zheng, Z., & Zheng, Y. (2026). Compared effectiveness of TNF inhibitors, JAK inhibitors, and csDMARDs in naïve rheumatoid arthritis patients: a real-world, observational, multi-center, retrospective cohort study in Northwest China. Clinical Rheumatology. https://doi.org/10.1007/s10067-026-08082-2
Vancouver
Wang J, Xiao G, Huo A, Jiang H, Li R, Li J, et al. Compared effectiveness of TNF inhibitors, JAK inhibitors, and csDMARDs in naïve rheumatoid arthritis patients: a real-world, observational, multi-center, retrospective cohort study in Northwest China. Clinical Rheumatology. 2026. doi:10.1007/s10067-026-08082-2
BibTeX
@article{Wang2026,
author = {Wang, Jiawei and Xiao, Guangzhi and Huo, Aixin and Jiang, He and Li, Rui and Li, Juan and Li, Xiaoyan and Liu, Yuhong and Zheng, Zhaohui and Zheng, Yan},
title = {Compared effectiveness of TNF inhibitors, JAK inhibitors, and csDMARDs in naïve rheumatoid arthritis patients: a real-world, observational, multi-center, retrospective cohort study in Northwest China},
journal = {Clinical Rheumatology},
year = {2026},
doi = {10.1007/s10067-026-08082-2}
}
EUVIMED